CDC recommends new RSV vaccine for infants under 8 months


The Centers for Disease Control and Prevention have recommended infants under eight months old get vaccinated for respiratory syncytial virus (RSV) starting in the fall. The disease is currently the "leading cause of hospitalization among infants in the U.S." Yearly, 58,000 to 80,000 children under 5 years of age, most of whom are infants, are hospitalized because of RSV. Some 100 to 300 children die from the disease every year.
The new vaccine, called nirsevimab, was approved in July. It is an antibody vaccine, which varies from typical vaccines. Regular vaccines "train the body's own immune defenses against the virus," while an antibody vaccine "works to directly fend off the virus in the body," CBS News reported. "This new RSV immunization provides parents with a powerful tool to protect their children against the threat of RSV," said CDC director Mandy Cohen. "RSV is the leading cause of hospitalizations for infants and older babies at higher risk and today we have taken an important step to make this life saving product available."
Almost all children will contract RSV by their second birthday, and the risk spikes every year in the winter and early spring months. The virus causes flu-like symptoms including fever, cough and runny nose. In children under three, "the illness may move into the lungs and cause coughing and wheezing," and in some cases "the infection turns to a severe respiratory disease," according to Cedars-Sinai. "I think that we will look back on this, in a short period of time, and see what a major impact this vote has had on the health and wellbeing of children," Dr. José Romero, director of the National Center for Immunization and Respiratory Diseases, said in a meeting for the CDC's Advisory Committee on Immunization Practices, which endorsed giving the vaccine.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
Home Depots are the new epicenters of ICE raids
In the Spotlight The chain has not provided many comments on the ongoing raids
-
Why does Trump keep interfering in the NYC mayoral race?
Today's Big Question The president has seemingly taken an outsized interest in his hometown elections, but are his efforts to block Zohran Mamdani about political expediency or something deeper?
-
The pros and cons of banning cellphones in classrooms
Pros and cons The devices could be major distractions
-
Quit-smoking ads are being put out
Under the radar The dissolution of a government-funded campaign could lead to more smokers in the future
-
Scientists are speeding up evolution
Under the radar Proteins can evolve in minutes
-
Sloth fever shows no signs of slowing down
The explainer The vector-borne illness is expanding its range
-
A new subtype of diabetes was found and it may require different treatment
Under the radar It is prevalent in Black Africans and Americans
-
Texas declares end to measles outbreak
Speed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Forever chemicals were found in reusable menstrual products. That is nothing new for women.
Under the Radar Toxic chemicals are all too common in such products
-
Scientists are developing artificial blood for use in emergencies
Under the radar It could aid in global blood shortages